Cleveland Clinic to confine use of Natrecor

The Pharmacy and Therapeutics Committee at the Cleveland Clinic recommended keeping Natrecor nesiritide from Johnson & Johnson (JNJ) on the formulary but set limits on its use. The clinic recommended that Natrecor be used only in patients with decompensated heart failure, at the FDA approved dose and in accordance with the FDA approved label. The committee also recommended that only a physician on the cardiovascular or critical care staff be able to prescribe the medication. ...